Abstract
Chronic lymphocytic leukemia (CLL) is a heterogeneous group of B-cell neoplasm. CLL is typically sensitive to a variety of cytotoxic agents, but relapse frequently occurs with conventional approaches. The treatment of CLL is evolving rapidly with the introduction of novel drugs, such as bendamustine, ofatumumab, lenalidomide, ibrutinib, idelalisib, veltuzumab, XmAb5574, navitoclax, dasatinib, alvespimycin, and TRU-016. This review summarizes the most current clinical experiences with these agents in the treatment of CLL.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bendamustine Hydrochloride
-
Humans
-
Lenalidomide
-
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
-
Nitrogen Mustard Compounds / administration & dosage
-
Nitrogen Mustard Compounds / adverse effects
-
Nitrogen Mustard Compounds / therapeutic use
-
Thalidomide / administration & dosage
-
Thalidomide / adverse effects
-
Thalidomide / analogs & derivatives
-
Thalidomide / therapeutic use
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents
-
Nitrogen Mustard Compounds
-
Thalidomide
-
Bendamustine Hydrochloride
-
Lenalidomide
-
ofatumumab